Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

The Journal of Clinical Psychiatry
Eric HermesRobert Rosenheck

Abstract

Establishing the minimum clinically important difference in the Positive and Negative Syndrome Scale (PANSS) is important to the interpretation of the research and clinical work conducted with this scale. This study employed both anchor-based and distributive methods to estimate the minimum clinically important difference for the PANSS by using data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, a large, multicenter trial for patients with schizophrenia. By using an equipercentile method, data from 1,442 individuals linked PANSS scores with both clinician and patient ratings on the Clinical Global Impressions scale (CGI). Data were also used to investigate the magnitude of the standard error of measurement (SEM), offering another estimate of the minimum clinically important difference. Cross-sectional, clinician-rated CGI-Severity of illness scores of 1 through 7 linked to PANSS scores of 32.4, 42.2, 57.5, 74.5, 93.0, 110.9, and 131.0, respectively. The minimum clinically important difference for PANSS scores using this scale equaled a 15.3-point (34.0%) change from baseline. A 1.96 SEM on the PANSS corresponded to a 16.5-point (36.2%) change from baseline. The minimum clinical...Continue Reading

References

Feb 1, 1991·Journal of Consulting and Clinical Psychology·N S Jacobson, P Truax
Dec 1, 1989·Controlled Clinical Trials·R JaeschkeG H Guyatt
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Aug 1, 1995·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·C A McHorney, A R Tarlov
Jun 1, 1993·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·E Lydick, R S Epstein
May 17, 2001·Schizophrenia Bulletin·J CramerUNKNOWN Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia
Jun 19, 2003·Journal of Clinical Epidemiology·Ross D CrosbyG Rhys Williams
Mar 19, 2004·Journal of Biopharmaceutical Statistics·Kathleen W Wyrwich
Apr 7, 2005·Psychiatric Services : a Journal of the American Psychiatric Association·Gary M BurlingameFrank M Rees
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Oct 4, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Stefan LeuchtRolf Engel
May 17, 2006·Journal of Clinical Psychopharmacology·Jonathan RabinowitzMarielle Eerdekens
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stefan LeuchtRolf R Engel
May 31, 2007·The Journal of Behavioral Health Services & Research·Susan V EisenAvron Spiro
Oct 18, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W Wolfgang Fleischhacker, Georg Kemmler

❮ Previous
Next ❯

Citations

Feb 18, 2016·Schizophrenia Research·Jessica DaganiGiovanni de Girolamo
Jul 7, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stephen Z LevineShitij Kapur
May 3, 2015·The British Journal of Psychiatry : the Journal of Mental Science·Paul HuttonJoanna Moncrieff
Apr 4, 2015·Journal of Clinical Psychopharmacology·Jimmy LeeGary Remington
Feb 14, 2015·Journal of Clinical Psychopharmacology·Gagan FervahaGary Remington
Jun 29, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Dan SiskindSteve Kisely
Jan 20, 2018·Expert Review of Pharmacoeconomics & Outcomes Research·Bertalan NémethBalázs Nagy
Jan 1, 2014·The Journal of Nervous and Mental Disease·Robert Rosenheck, Haiqun Lin
Aug 23, 2018·Journal of Comparative Effectiveness Research·Claire Ainsworth
Jan 18, 2018·Social Psychiatry and Psychiatric Epidemiology·Cristina DomenechJosep Maria Haro
Mar 28, 2019·JAMA Psychiatry·Shitij Kapur, Marcus Munafò
Jun 22, 2017·The Psychiatric Quarterly·Elina A StefanovicsJohn H Krystal
Mar 10, 2015·The Cochrane Database of Systematic Reviews·Benno HartungStefan Leucht
Nov 2, 2019·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Roger VilardagaFrancis J Mcclernon
Nov 23, 2017·Clinical Schizophrenia & Related Psychoses·Dawn VelliganCharles Ruetsch
Apr 30, 2019·Frontiers in Psychiatry·Abigail C WrightKathryn Greenwood
May 1, 2019·Child and Adolescent Mental Health·Paul A Tiffin, Lewis W Paton
Jan 6, 2021·Journal of Neurodevelopmental Disorders·Alexander KolevzonJudith Jaeger
Mar 12, 2021·Scientific Reports·Manit SrisurapanontNarong Maneeton
Oct 14, 2021·The Cochrane Database of Systematic Reviews·Yasushi TsujimotoYuki Kataoka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Related Papers

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
E Lydick, R S Epstein
Schizophrenia Research
Stefan LeuchtRolf R Engel
© 2021 Meta ULC. All rights reserved